Brought to you by 
Google Ventures leads Adimab's $8.2mm Series D financing
28 Oct 2009
Executive Summary
Looking to exploit Google's computational skills in drug discovery, newly established Google Ventures has led an $8.2mm Series D financing for Adimab (fully human, yeast-derived antibodies). The round consisted of ten investors including returning shareholders Polaris Ventures, SV Life Sciences, OrbiMed Advisors, and Borealis Ventures. A managing partner from Google Ventures has joined the start-up's board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Google Ventures leads Adimab's $8.2mm Series D financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice